Skip to main content
. 2015 Aug 12;5(2):e1074374. doi: 10.1080/2162402X.2015.1074374

Figure 5.

Figure 5.

The inhibition on angiogenesis and inflammation in the tumors resulting from the dual delivery of celecoxib (CXB) and anti-PD-1 mAb (αPD-1). C57BL/6 mice received the treatments with the blank hydrogel (gel) and the hydrogels delivering CXB (+ CXB), anti-PD-1 mAb (+ αPD-1), or both (+ CXB + αPD-1) at Day 7 after the inoculation of 1.0 × 105 B16-F10 cells. The tumors were surgically taken from the mice 7 d after the treatments. (A) The representative images of blood vessel CD31 immunohistochemical staining for the tumors. (B) Quantification of the number of microvessels. (C) Quantification of the microvessel surface percentage. (D–N) The relative mRNA levels of CXCL10 (D), CXCL9 (E), IL-1β (I), IL-6 (J), COX2 (K), the protein levels of CXCL10 (F), CXCL9 (G), IFN-γ (H), IL-1β (L) and IL-6 (M) and PGE2 concentrations (N) within the tumors in the corresponding treatment groups. *P < 0.05, **P < 0.01, N.S., not significant, Student's t-tests. The asterisk or “N.S.” without a line underneath indicates the comparison to the blank hydrogel group. Error bars represent the standard error of the mean.